Clinical Trials Sponsored by AbbVie Biopharmaceuticals LTD

Total 440 results

Sheba Medical Center
AbbVie Biopharmaceuticals LTD; Intel Electronics Ltd.

Completed

Assessment of Fluctuating Parkinson's Disease With Sensor-based Home Monitoring

Parkinson Disease

Israel
Ascend Biopharmaceuticals Ltd

Completed

Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor

Basal Cell Nevus Syndrome | Basal Cell Carcinoma

Australia
Kangpu Biopharmaceuticals, Ltd.

Active, not recruiting

Phase 1b/2a Study to Evaluate Safety and Efficacy of KPG-818 in SLE (Lupus)

SLE; Drug

United States
Ascend Biopharmaceuticals Ltd

Completed

A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma (ASN-002-001)

Basal Cell Nevus Syndrome | Skin Neoplasm | Nodular Basal Cell Carcinoma of Skin

Australia
Kangpu Biopharmaceuticals, Ltd.

Recruiting

Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects

Hematological Malignancies

United States
Kangpu Biopharmaceuticals, Ltd.

Completed

Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients

Castration-Resistant Prostate Cancer

United States
Ascend Biopharmaceuticals Ltd

Suspended

Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)

Basal Cell Carcinoma in Basal Cell Nevus Syndrome

United States
Kangpu Biopharmaceuticals, Ltd.

Completed

Safety, Tolerability and Pharmacokinetics of KPG-818 in Healthy Subjects

Systemic Lupus Erythematosus

United States
Paradigm Biopharmaceuticals USA (INC)

Active, not recruiting

Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain

Osteoarthritis, Knee

Australia, United States
Paradigm Biopharmaceuticals USA (INC)

Active, not recruiting

An Observational Follow-up Study to Evaluate Duration of Treatment Effect of Pentosan Polysulfate Sodium in Participants With Knee Osteoarthritis Pain

Osteoarthritis, Knee

United States, Australia
Tasly Biopharmaceuticals Co., Ltd.

Recruiting

A Trial to Evaluate the Safety Tolerability and Pharmacokinetics of B1344 by Subcutaneous Injection in Healthy Subjects

Nonalcoholic Steatohepatitis

United States
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)

Subcutaneous Fat

Australia
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)

Subcutaneous Fat

United States, Australia
Tasly Biopharmaceuticals Co., Ltd.

Completed

A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism (ERUPTE)

Acute Pulmonary Embolism

China
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat

Subcutaneous Fat

Australia
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Recruiting

A Phase 1/2 Study of Donafenib in Combination With KN046 in Advanced Gastrointestinal Tumors

Advanced Gastrointestinal Tumors

China
Caliway Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas

Dercum's Disease
Tasly Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Study of B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid Tumors

Neoplasms Malignant

China
Suzhou Connect Biopharmaceuticals, Ltd.

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe AD

Atopic Dermatitis

China
Caliway Biopharmaceuticals Co., Ltd.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2)

Cellulite

United States
Suzhou Connect Biopharmaceuticals, Ltd.

Completed

A Study to Evaluate the Pharmacokinetics Similarity of CBP-201 in Healthy Adult Chinese Subjects

Healthy Adult Subjects

China
Suzhou Connect Biopharmaceuticals, Ltd.

Terminated

A Study to Evaluate CBP-201, Rademikibart, in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps

Chronic Rhinosinusitis With Nasal Polyps

United States, China, Poland, Spain, Ukraine
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 1)

Cellulite

United States
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease Lipomas

Dercum's Disease

United States
Suzhou Connect Biopharmaceuticals, Ltd.

Completed

A Study On Human Mass Balance And Biotransformation

Healthy Adult Subjects

China
Caliway Biopharmaceuticals Co., Ltd.

Recruiting

A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.

Subcutaneous Fat

United States
Tasly Biopharmaceuticals Co., Ltd.

Active, not recruiting

rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2) (PROST-2)

Acute Ischemic Stroke

China
Suzhou Connect Biopharmaceuticals, Ltd.

Completed

A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)

Moderate to Severe Ulcerative Colitis

United States, China, Pakistan, Ukraine
Suzhou Connect Biopharmaceuticals, Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China

Moderate-to-severe Atopic Dermatitis

China
Suzhou Connect Biopharmaceuticals, Ltd.

Completed

Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation

Moderate to Severe Persistent Asthma

United States, China, Hungary, Korea, Republic of, Poland
Caliway Biopharmaceuticals Co., Ltd.

Active, not recruiting

A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat

Subcutaneous Fat

United States
Suzhou Connect Biopharmaceuticals, Ltd.

Completed

A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis

Moderate-to-severe Atopic Dermatitis

United States, Australia, China, New Zealand
Suzhou Connect Biopharmaceuticals, Ltd.

Withdrawn

CBP-201 in Adolescent and Adult Patients With Moderate-to-severe Atopic Dermatitis

Atopic Dermatitis

United States
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers

Subcutaneous Fat

United States
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy Volunteers

Subcutaneous Fat

Australia
Tasly Biopharmaceuticals Co., Ltd.

Completed

Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST)

Acute Ischaemic Stroke

China
Tasly Biopharmaceuticals Co., Ltd.

Completed

Thrombolysis With rhPro-UK in 4.5-6 Hours After Acute Ischemic Stroke in a Double-blinded,Controlled Trial (PROUD)

Acute Ischaemic Stroke

China
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Australia Pty Ltd

Completed

Phase 2 Study of NGM282 in Patients With Type 2 Diabetes

Diabetes Mellitus

Australia, New Zealand
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Australia Pty Ltd

Completed

Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States, Australia, Puerto Rico
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Australia Pty Ltd

Completed

Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States, Australia, New Zealand
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Australia Pty Ltd

Completed

Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States, Australia
Beijing Kanova Biopharmaceutical Co., LTD

Active, not recruiting

Phase I of XKH001Injection in Healthy Adults

Healthy Adults

China
Beijing Kanova Biopharmaceutical Co., LTD

Not yet recruiting

XKH001 Injection in Healthy Subjects

Asthma
Binhui Biopharmaceutical Co., Ltd.

Not yet recruiting

OH2 Administered by Intratumoral Injection

Solid Tumor
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of XZB-0004 in Patients With Solid Tumors

NSCLC | Advanced Solid Tumor

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of KM602 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

To Evaluate the Phase I Clinical Study of XZB-0004 in Patients With AML and MDS

AML | MDS

China
Binhui Biopharmaceutical Co., Ltd.

Recruiting

OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients With Advanced Liver Cancer

Advanced Liver Cancer

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Clinical Trial of XZP-3287 for Material Balance

Healthy Male Subjects

China
Xuanzhu Biopharmaceutical Co., Ltd.

Recruiting

A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors | Locally Advanced or Metastatic Non-small Cell Lung Cancer

China

Clinical Trials Sponsored by AbbVie Biopharmaceuticals LTD

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations